IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT) intends to complete an offering in order to
capitalize on the introduction of its novel antimicrobial technology to address
hospital-acquired infections (HAI).


HAI's cause 99,000 fatalities annually in the US, at a cost of $33 billion to
the healthcare system. The primary cause is attributed to the use of medical
devices particularly blood and urinary catheters and tubes to assist breathing.


Innovotech has developed a novel antimicrobial compound that possesses unique
properties making it ideal for coating medical devices to control HAI's. 


Innovotech is very familiar with this field as its contract research business
develops scientific studies for medical device companies to support claims for
antimicrobial coatings. The company has Material Transfer Agreements in place
with three companies who have expressed interest in the compound.


The offering, subject to regulatory approval, is comprised of up to 1,666,667
units ("Units") at a price of $0.30 per Unit for gross proceeds of up to
$500,000 by way of a private placement (the "Offering"). Each Unit is comprised
of one (1) common share ("Common Share") and one (1) Common Share purchase
warrant ("Warrant"). Each Warrant entitles the holder to purchase one (1)
additional Common Share at a price of $0.40 per Common Share for a period of
three (3) years following the date of closing. 


About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are organized
communities of microorganisms that exist in virtually every natural environment
and are responsible for a host of diseases in human health, animal health and
agriculture. There are few products or regulatory standards, aside from those of
Innovotech, designed specifically for biofilm-forming organisms. 


Innovotech has a broad range of products that address the issue of biofilms
within a number of different industries, including commercially available
products in three market segments; the MBEC Assay(TM), bioFILM PA(TM),
InnovoSCEPT-Human and InnovoSCEPT-Veterinary tests. The MBEC Assay(TM) is a high
throughput biofilm growth device that was recently approved as an ASTM
International standard. bioFILM PA(TM) and InnovoSCEPT-Human are the first
diagnostic tests to assist physicians in the selection of the most effective
antibiotic treatment for patients with biofilm-based chronic infections, while
the InnovoSCEPT veterinary tests are designed to determine the most effective
antibiotic treatment for chronic infections in both large and small animals. 


Innovotech also has three products in advanced stages of development; Agress(R)
is a unique, environmentally friendly seed treatment and plant spray designed to
protect crops against both bacterial and fungal infections, AgreGuard(TM) is a
unique antimicrobial for coating medical devices such as catheters, and
SaniLux(TM) is a light-activated, natural hard surface sanitizer.


Connect with us:

Website: www.innovotech.ca

Blog: www.cf-test.ca

Twitter: www.twitter.com/innovotech

Facebook: www.facebook.com/innovotech

FOR FURTHER INFORMATION PLEASE CONTACT: 
Innovotech Inc.
Ken Boutilier
President and CEO
(780) 448-0585 ext. 221
(780) 424-0941 (FAX)
ken.boutilier@innovotech.ca
www.innovotech.ca

Grafico Azioni Innovotech (TSXV:IOT)
Storico
Da Nov 2024 a Dic 2024

Grafico Azioni Innovotech (TSXV:IOT)
Storico
Da Dic 2023 a Dic 2024